Bryan, Garnier & Co started coverage on shares of Travere Therapeutics (NASDAQ:TVTX – Get Rating) in a report issued on Wednesday morning, MarketBeat reports. The brokerage issued a sell rating and a $17.00 target price on the stock.
Several other brokerages have also recently weighed in on TVTX. Barclays lowered their price target on shares of Travere Therapeutics to $37.00 in a research report on Tuesday, August 9th. Evercore ISI decreased their target price on shares of Travere Therapeutics to $35.00 in a research report on Tuesday, August 9th. Piper Sandler decreased their target price on shares of Travere Therapeutics from $41.00 to $39.00 in a research report on Monday, August 15th. SVB Leerink increased their target price on shares of Travere Therapeutics from $42.00 to $45.00 and gave the company an outperform rating in a research report on Friday, August 5th. Finally, Canaccord Genuity Group reissued a buy rating and set a $42.00 target price on shares of Travere Therapeutics in a research report on Thursday, July 14th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat, Travere Therapeutics has an average rating of Moderate Buy and an average price target of $36.71.
Travere Therapeutics Price Performance
Shares of TVTX opened at $24.90 on Wednesday. The company has a 50 day moving average price of $26.18 and a 200-day moving average price of $25.48. Travere Therapeutics has a fifty-two week low of $20.80 and a fifty-two week high of $31.65. The stock has a market capitalization of $1.58 billion, a PE ratio of -6.77 and a beta of 0.58. The company has a debt-to-equity ratio of 2.39, a quick ratio of 4.65 and a current ratio of 4.71.
Institutional Inflows and Outflows
About Travere Therapeutics
Travere Therapeutics, Inc, a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.
- Get a free copy of the StockNews.com research report on Travere Therapeutics (TVTX)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.